Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $1,476,000.00 in Stock

Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) CEO John M. Evans sold 60,000 shares of the stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $24.60, for a total transaction of $1,476,000.00. Following the completion of the sale, the chief executive officer now directly owns 938,659 shares in the company, valued at $23,091,011.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Beam Therapeutics Trading Up 0.4 %

Shares of BEAM traded up $0.09 during mid-day trading on Wednesday, reaching $23.50. The company's stock had a trading volume of 610,986 shares, compared to its average volume of 1,253,272. The stock has a market cap of $1.93 billion, a PE ratio of -13.15 and a beta of 1.86. Beam Therapeutics Inc. has a 52 week low of $16.95 and a 52 week high of $49.50. The company's fifty day moving average price is $25.97 and its two-hundred day moving average price is $25.78.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($1.11) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.02. Beam Therapeutics had a negative net margin of 40.56% and a negative return on equity of 16.22%. The firm had revenue of $11.80 million during the quarter, compared to analyst estimates of $14.18 million. During the same period in the previous year, the business posted ($1.08) EPS. The business's quarterly revenue was down 41.3% on a year-over-year basis. Research analysts anticipate that Beam Therapeutics Inc. will post -4.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BEAM. Barclays lowered their target price on shares of Beam Therapeutics from $33.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Wednesday, August 7th. Stifel Nicolaus raised their target price on shares of Beam Therapeutics from $66.00 to $69.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $27.00 target price on shares of Beam Therapeutics in a research note on Thursday, September 19th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Beam Therapeutics in a research note on Thursday, August 22nd. Finally, JPMorgan Chase & Co. raised their target price on shares of Beam Therapeutics from $45.00 to $48.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $44.18.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BEAM. ARCH Venture Management LLC purchased a new position in shares of Beam Therapeutics in the second quarter worth $127,530,000. Farallon Capital Management LLC increased its position in Beam Therapeutics by 75.4% during the 2nd quarter. Farallon Capital Management LLC now owns 7,913,123 shares of the company's stock valued at $185,404,000 after purchasing an additional 3,401,370 shares during the period. Darwin Global Management Ltd. purchased a new position in Beam Therapeutics during the 1st quarter valued at $70,032,000. Price T Rowe Associates Inc. MD increased its position in Beam Therapeutics by 3,137.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,246,189 shares of the company's stock valued at $41,175,000 after purchasing an additional 1,207,699 shares during the period. Finally, Bellevue Group AG increased its position in Beam Therapeutics by 71.7% during the 1st quarter. Bellevue Group AG now owns 1,193,121 shares of the company's stock valued at $39,421,000 after purchasing an additional 498,300 shares during the period. 99.68% of the stock is owned by hedge funds and other institutional investors.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.